Compare Davita Inc (DVA) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs VanEck Vietnam ETF — how do they compare? Davita Inc trades at $179.75 (market cap $11.72B), while VanEck Vietnam ETF trades at $17.77. The key difference: Davita Inc is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| DVA | VNM | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | Sector/Thematic |
52-Week High | $240.96 | $19.80 |
52-Week Low | $103.87 | $16.34 |
Enterprise Value | $24.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
VNM trades at $17.44, showing minimal daily change. Technical indicators are bullish overall, with moving averages signaling strength, while oscillators remain neutral. Key support and resistance levels are tightly clustered around $17 and $18. Recent news highlights regional capital flows and Vietnam-specific challenges, including power grid strain and FTSE Russell's emerging market reclassification affecting the ETF's performance.
The outlook is mixed, with technical strength countered by fundamental data gaps and external risks. Investment opportunity hinges on Vietnam's economic trajectory and foreign investment inflows, but risks include macroeconomic pressures and domestic infrastructure issues. Clarity on financial metrics is essential for a complete assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
